NNVC
NanoViricides Inc (NNVC)
Healthcare • NYSE MKT • $1.55+9.15%
- Symbol
- NNVC
- Exchange
- NYSE MKT
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.55
- Daily Change
- +9.15%
- Market Cap
- $33.47M
- Trailing P/E
- N/A
- Forward P/E
- -4.43
- 52W High
- $2.23
- 52W Low
- $0.85
- Analyst Target
- $6.50
- Dividend Yield
- N/A
- Beta
- 1.54
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat seve…
Company websiteResearch NNVC on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.